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Various cutaneous manifestations of COVID-19 have been described and awareness of these
findings is beneficial for clinicians for an accurate diagnosis.
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Clinical Findings

We present a case of skin findings consistent with acral microthrombi induced changes in an
elderly gentleman who was positive for COVID-19.

Outcomes

The patient had a mild course of COVID-19. Cutaneous findings resolved after one week
from presentation with supportive care.

Conclusions

This case highlights the importance of awareness of manifestations of COVID-19, which may
assist in timely diagnosis and prevention of transmission.
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Introduction

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19)
has presented in many unusual ways that have
continued to intrigue the medical community.
Its presentation ranges from asymptomatic to severe pulmonologic complications and
death. Additionally, cutaneous manifestations
have been well documented and can occur in
up to 20% of cases.1 While so-called “COVID
Toes” have become pervasive in the popular
and medical literature, skin findings associated
with COVID-19 range from more to less specific and include erythematous, petechial, urticarial and vesicular rashes.1-3 As the pandemic
continues to evolve, it is important to make
note of unique presentations and highlight the
importance of reporting confirmed or suspected cutaneous associations with COVID-19. We
present a case that highlights a suspected cutaneous manifestation in an elderly gentleman
with a diagnosis of COVID-19.

Clinical Findings

An elderly gentleman with a diagnosis of
COVID-19 and multiple comorbidities including
mild cognitive impairment, hypertension, sick
sinus syndrome and moderate pulmonary hypertension, presented initially via telemedicine
to his primary care physician due to the sudden
onset of painful, blue hands and fingertips. He
reported difficulty with grasping objects due
to the discomfort. He and his wife were diagnosed with COVID-19 via polymerase chain
reaction (PCR) at an outside facility 3 weeks
prior to presentation. He had no new medications. He had minimal respiratory symptoms
despite multiple comorbidities. Examination
of the hands revealed violaceous discoloration
of the fingertips with multiple linear erosions.
Reportedly, he had preserved capillary refill and
brisk distal pulses.after acceptance, the D-dimer value was measured as 450 μg/L.
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Outcomes

The patient was evaluated by dermatology
with a “store-and-forward” method. In this
scenario, a photograph was obtained by the
patient (Figure 1) and sent to the referring
physician. This photo demonstrates dusky, erythematous digits with linear fissuring. Biopsy
evaluation was not possible in this setting. In
light of the recent diagnosis of COVID-19 and
sudden onset of painful, violaceous fingertips,
the diagnosis of acro-ischemia secondary to
COVID-19 was made. Additionally, signs of
irritant contact dermatitis were visible in the
photograph. These findings were attributed
to frequent handwashing by the patient in
an effort to avoid transmission of COVID-19.
Other diagnoses were considered at this time,
including pernio and connective tissue diseases.
These diagnoses were considered less likely as
an isolated finding that improved with recovery
from COVID-19. Acrocyanosis associated with
exposure to cool temperatures was also considered, but in our patient’s case he had no known
exposure and no improvement with warming.
The discoloration and ulceration of his fingertips resolved after 1 week with the only intervention being emollients. He continued to do

well at a subsequent 1-month follow up and
had no evidence of respiratory or dermatologic
sequelae.

Discussion

This case is an example of one of the possible
unusual presentations of COVID-19 that clinicians may be presented with in their practice,
whether in person or while practicing telemedicine. Limitations of this investigation include
lack of in-person assessment and routine
histopathological examination. Without a more
thorough investigation, it is challenging to say
if these lesions represented acral ischemia or
pernio-like lesions. In either regard, infection
with COVID-19 is believed to be the cause of
this patient’s skin findings.
Cutaneous manifestations of COVID-19 described in the literature vary widely and include both the more well-known pernio- or
chillblains-like lesions and the less well-known
presentations, including erythematous rash,
petechial rash, livedo reticularis type lesions,
urticarial rash and vesicular rash.1-3 While the
most frequently discussed cutaneous find-

Figure 1. Linear and scattered erosions with background faint dusky erythema on bilateral distal
fingertips, consistent with irritant contact dermatitis in a COVID-19 positive patient.
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ing may be “COVID Toes,” the most common
finding is a generalized morbilliform, or measles-like, rash.3 Morbilliform rash is a relatively
nonspecific finding and may be overlooked as
related to COVID-19 since it is frequently attributed to a drug reaction. Pernio-like findings
are the most frequently reported cutaneous lesions associated with COVID-19 and have been
described more frequently in young, otherwise
healthy individuals with mild COVID-19.4,5 These
findings are in partial contrast to the patient in
this case, who was elderly with multiple comorbidities, though with a mild presentation of
COVID-19. Additionally, feet have been affected
more than hands, as in this case.4,5 Timing of
the onset of these lesions is from 3 to 13 days
after diagnosis.3 Pernio-like lesions are associated with a generally mild course, whereas presentation with retiform purpura is associated
with more severe disease and is seen in ill, hospitalized patients.6 However, emerging data is
calling into question any true association with
pernio-like lesions and COVID-19 infection.7
In our case, the patient responded with observation and conservative measures, such as
warming and emollients. If the patient’s symptoms had ceased to improve, a trial of topical
steroids would have been a reasonable option.
Topical corticosteroids would be beneficial for
treatment of the fissuring related to contact
dermatitis and have been used to treat pernio.8
In general, treatment for pernio-like lesions of
COVID-19 is similar to that of primary pernio
and includes topical steroids, physical warming
and calcium channel blockers.9
The pathophysiology behind these findings is
unclear, but theories exist regarding the different presentations of COVID-19 associated skin
findings. In the case of pernio-like lesions, the
most widely accepted theory is that an abundance of type 1 interferons (INF-1) and a cytokine storm lead to the microangiopathy that
characterizes pernio.3,4 It is possible that some
of the cutaneous findings can be attributed to
viral particles in the blood causing an immune
response that leads to a lymphocytic vasculitis,
which leads to destruction of the vasculature.3
Keratinocytes themselves may or may not be a
direct target of the immune response, or they
may be damaged due to nearby inflammation.3,5
Another potential factor in the development
of skin lesions is a COVID-19 associated coagulopathy, which has been implicated in cases

of thromboembolism and lab abnormalities
such as antiphospholipid antibodies and elevated D-dimer.5,10,11 It is postulated that multiple
microthrombi lead to reduced blood flow to
the cutaneous vasculature, leading to clinically
evident acral ischemia.3
Challenges facing clinicians are multiple and include the speed at which information about the
virus emerges and nonspecific skin findings associated with COVID-19. Additionally, the ability
to accurately evaluate those suspected with
the virus can be complicated by the use of telemedicine or delayed presentation. Information
about this disease is widely available but rapidly
changing. An algorithm approach has been
suggested to help the dermatologist or other
clinician faced with a rash in a patient who has
a suspected or confirmed case of COVID-19
with a tool to classify the disease.2 A simplified
algorithmic approach adopted from Orgega-Quijano et al. is to delineate if the rash is
non-blanching or blanching.2 If it is non-blanching, a diagnosis of acral ischemia or livedo
reticularis should be considered. Clinicians who
are concerned about a rash are encouraged to
take photographs (with patient permission) if
dermatology evaluation is not readily available.
In our case, a “store-and-forward” method of
evaluation was used and demonstrates the
changing landscape of gathering historical and
physical information in treating patients. This
method highlights the need of systems in place
to accurately and quickly evaluate complaints in
individuals with suspected or confirmed infections. Furthermore, as individuals may be otherwise asymptomatic, recognition of cutaneous
findings associated with COVID-19 is of great
importance to guide testing.
Collective understanding of the varied presentations of COVID-19 is evolving with the course
of this unprecedented pandemic. A collaborative database supported by the American
Academy of Dermatology (AAD) exists for
any clinician who suspects COVID-19 related
skin manifestations. Clinicians who suspect a
COVID-10 related skin finding are encouraged
to report this to the AAD COVID Database
(www.aad.org/covidregistry).
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